This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Portrazza

Eli Lilly & Company

Drug Names(s): IMC-11F8, LY3012211

Description: IMC-11F8 is a second generation Erbitux. Unlike chimeric Erbitux, IMC-11F8 is a fully human monoclonal antibody that binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor [EGF] and other ligands, such as transforming growth factor-alpha.

Deal Structure: Dyax and AstraZeneca
IMC-11F8 was selected from a Dyax Phage Display library. In 1997, Dyax licensed its Ladner Phage Display patents to CAT and CAT granted certain limited rights to Dyax in relation to its Phage Display technology patents.

In January 2003, CAT and Dyax agreed to expand this access and to grant freedom to operate under each other's Phage Display technology patents. CAT granted Dyax worldwide licences for research purposes accessing all the Phage Display technology patents controlled by CAT and options for licences to develop therapeutic and diagnostic antibody products under CAT's patents. In return CAT will receive milestone and royalty payments on antibody products successfully developed by Dyax and its licensees. In January 2005, Dyax announced that two fully human monoclonal antibodies from Dyax's proprietary phage display libraries, IMC- 11F8 and IMC-1121B, entered Phase I clinical development at ImClone Systems. Accordingly, CAT received a...See full deal structure in Biomedtracker

Partners: AstraZeneca PLC Shire Pharmaceuticals Group PLC


Portrazza News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug